Genetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle

ABSTRACT Recombinant adeno-associated virus (rAAV) vectors are promising human gene transfer vectors, because they mediate long-term gene expression in vivo. The vector DNA form responsible for sustained gene expression has not been clearly defined, but it has been presumed that the vector integrates to some degree and persists in this manner. Using two independent methods, we were unable to identify rAAV integrants in mouse muscle. In the first approach, we were unable to recover host cell-vector DNA junctions from a lambda phage library generated using transduced mouse muscle DNA that contained a high vector copy number. Following this result, we devised a PCR assay based on the principle that integrated rAAV vector sequences could be amplified using primers specific for mouse interspersed repetitive sequences (B1 elements). Using this assay, we analyzed transduced mouse muscle DNA isolated from 6 to 57 weeks after injection and did not detect amplification above background levels. Based on the demonstrated sensitivity of the assay, these results suggested that >99.5% of vector DNA was not integrated. Additional analyses using a novel DNA exonuclease showed that the majority of the rAAV vector DNA in muscle persisted over time as transcriptionally active monomeric and concatameric episomes.

[1]  E. Terwilliger,et al.  Adeno-Associated Virus Vector-Mediated Transgene Integration into Neurons and Other Nondividing Cell Targets , 1998, Journal of Virology.

[2]  C. G. Miyada,et al.  Oligonucleotide probes for the screening of recombinant DNA libraries. , 1987, Methods in enzymology.

[3]  Theresa A. Storm,et al.  Recruitment of Single-Stranded Recombinant Adeno-Associated Virus Vector Genomes and Intermolecular Recombination Are Responsible for Stable Transduction of Liver In Vivo , 2000, Journal of Virology.

[4]  D. Bohl,et al.  Structure of Adeno-Associated Virus Vector DNA following Transduction of the Skeletal Muscle , 1999, Journal of Virology.

[5]  Philip R. Johnson,et al.  Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. , 1999, Human gene therapy.

[6]  Prerna Sharma,et al.  Circular Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural Characteristics Responsible for Long-Term Episomal Persistence in Muscle Tissue , 1998, Journal of Virology.

[7]  C. Giraud,et al.  Recombinant junctions formed by site-specific integration of adeno-associated virus into an episome , 1995, Journal of virology.

[8]  J. Tratschin,et al.  Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells , 1985, Molecular and cellular biology.

[9]  C. Petropoulos,et al.  Plasmid integration, amplification and cytogenetics in CHO cells: questions and comments. , 1994, Biologicals : journal of the International Association of Biological Standardization.

[10]  R. Samulski,et al.  Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Skopek,et al.  International Commission for Protection Against Environmental Mutagens and Carcinogens. Working paper no. 3. Somatic mutant frequency, mutation rates and mutational spectra in the human population in vivo. , 1994, Mutation research.

[12]  Lynne,et al.  Site-specific integration by adeno-associated virus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Philip R. Johnson,et al.  Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. , 1997, Human gene therapy.

[14]  John Carbon,et al.  A colony bank containing synthetic CoI EI hybrid plasmids representative of the entire E. coli genome , 1976, Cell.

[15]  Kotoku Kurachi,et al.  Kinetics of Recombinant Adeno-Associated Virus-Mediated Gene Transfer , 2000, Journal of Virology.

[16]  J. Wolff,et al.  Direct gene transfer into muscle. , 1994, Vaccine.

[17]  K. High.  Gene transfer as an approach to treating hemophilia. , 2001, Circulation research.

[18]  Theresa A. Storm,et al.  Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo , 2001, Journal of Virology.

[19]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[20]  J. Wilson,et al.  In vivo selection of hepatocytes transduced with adeno-associated viral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  N. Muzyczka,et al.  Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Frederic D. Bushman,et al.  A quantitative assay for HIV DNA integration in vivo , 2001, Nature Medicine.

[23]  A. Gown,et al.  Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors , 1997, Nature Genetics.

[24]  T. Flotte,et al.  In vivo model of adeno-associated virus vector persistence and rescue , 1996, Journal of virology.

[25]  Philip R. Johnson,et al.  Cell lines for the production of recombinant adeno-associated virus. , 1995, Human gene therapy.

[26]  D. Housman,et al.  Targeted integration of adeno‐associated virus (AAV) into human chromosome 19. , 1991, The EMBO journal.

[27]  P. Felgner,et al.  Cationic liposome mediated transfection. , 1989, Proceedings of the Western Pharmacology Society.

[28]  T. Flotte,et al.  Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Wallace Rb,et al.  Oligonucleotide probes for the screening of recombinant DNA libraries , 1987 .

[30]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[31]  A. Kimmel,et al.  Guide to molecular cloning techniques. , 1987, Methods in enzymology.

[32]  S. Hoffman,et al.  Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. , 1999, Human gene therapy.

[33]  M. Weitzman,et al.  Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Flotte,et al.  Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus , 1998, The Lancet.

[35]  R. Samulski,et al.  Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro , 1997, Journal of virology.

[36]  Daniel G. Miller,et al.  Chromosomal effects of adeno-associated virus vector integration , 2002, Nature Genetics.

[37]  S. Kochanek,et al.  Frequency and Stability of Chromosomal Integration of Adenovirus Vectors , 1999, Journal of Virology.

[38]  P. Lohman.  International Commission for Protection against Environmental Mutagens and Carcinogens. , 1980, Cancer research.

[39]  P. Collis,et al.  Adeno-associated virus general transduction vectors: analysis of proviral structures , 1988, Journal of virology.

[40]  T. Flotte,et al.  Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model , 1999, Journal of Virology.

[41]  R. Samulski,et al.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector , 1996, Journal of virology.

[42]  M. Kay,et al.  Isolation of Recombinant Adeno-Associated Virus Vector-Cellular DNA Junctions from Mouse Liver , 1999, Journal of Virology.

[43]  M. Kay,et al.  The kinetics of rAAV integration in the liver , 1998, Nature Genetics.

[44]  A. Nienhuis,et al.  Recombinant adeno-associated virus-mediated high-efficiency, transient expression of the murine cationic amino acid transporter (ecotropic retroviral receptor) permits stable transduction of human HeLa cells by ecotropic retroviral vectors , 1996, Journal of virology.

[45]  W. W. Nichols,et al.  Plasmid DNA Vaccines: Investigation of Integration into Host Cellular DNA following Intramuscular Injection in Mice , 2001, Intervirology.

[46]  T. M. Williams,et al.  Evolutionary History of B1 Retroposons in the Genus Mus , 2000, Journal of Molecular Evolution.

[47]  R. Chen,et al.  Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression. , 1999, Journal of drug targeting.

[48]  D. Russell,et al.  Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Laipis,et al.  Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors , 2001, Gene Therapy.

[50]  Yulong Zhang,et al.  Concatamerization of Adeno-Associated Virus Circular Genomes Occurs through Intermolecular Recombination , 1999, Journal of Virology.

[51]  H. Temin.  Overview of biological effects of addition of DNA molecules to cells , 1990, Developments in biological standardization.

[52]  Hook Eb.  International Commission for Protection against Environmental Mutagens and Carcinogens. ICPEMC meeting report no. 3. Is the incidence of Down syndrome increasing? , 1983, Mutation research.

[53]  T. Flotte,et al.  Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. , 1996, Gene therapy.

[54]  J. Lebkowski,et al.  Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types , 1988, Molecular and cellular biology.

[55]  H. Certa,et al.  Genotoxicity studies with chloroethane. , 1994, Mutation research.

[56]  T. Flotte,et al.  Safety and Biological Efficacy of an Adeno‐Associated Virus Vector–Cystic Fibrosis Transmembrane Regulator (AAV‐CFTR) in the Cystic Fibrosis Maxillary Sinus , 1999, The Laryngoscope.

[57]  T. Flotte,et al.  Effect Of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[58]  F. Graham,et al.  Manipulation of adenovirus vectors. , 1991, Methods in molecular biology.

[59]  R. Hohlfeld,et al.  The immunobiology of muscle. , 1994, Immunology today.

[60]  James M. Wilson,et al.  Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.

[61]  R. Samulski,et al.  Adeno-associated virus vectors for gene therapy: more pros than cons? , 2000, Molecular medicine today.

[62]  P. Malik,et al.  Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line , 1997, Journal of virology.

[63]  D. Russell,et al.  Adeno-associated virus vector integration junctions , 1997, Journal of virology.

[64]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[65]  W. Hauswirth,et al.  Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.